Drug Type Small molecule drug |
Synonyms Axitinib (JAN/USAN), 阿西替尼, AG-013736 + [13] |
Target |
Action antagonists |
Mechanism VEGFR1 antagonists(Vascular endothelial growth factor receptor 1 antagonists), VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists), VEGFR3 antagonists(Vascular endothelial growth factor receptor 3 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (27 Jan 2012), |
RegulationFast Track (United States), Orphan Drug (United States) |
Molecular FormulaC22H18N4OS |
InChIKeyRITAVMQDGBJQJZ-FMIVXFBMSA-N |
CAS Registry319460-85-0 |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Metastatic Renal Cell Carcinoma | China | 22 Apr 2025 | |
| Unresectable Renal Cell Carcinoma | China | 22 Apr 2025 | |
| Renal Cell Carcinoma | Japan | 29 Jun 2012 | |
| Advanced Renal Cell Carcinoma | United States | 27 Jan 2012 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Glycogen Storage Disease Type II | Phase 3 | United States | 27 Apr 2026 | |
| Nonproliferative diabetic retinopathy | Phase 3 | United States | 17 Nov 2025 | |
| Wet age-related macular degeneration | Phase 3 | United States | 29 Jan 2024 | |
| Wet age-related macular degeneration | Phase 3 | Argentina | 29 Jan 2024 | |
| Locally Advanced Renal Cell Carcinoma | Phase 3 | - | 16 Sep 2016 | |
| Advanced cancer | Phase 3 | Germany | 01 Nov 2011 | |
| Advanced cancer | Phase 3 | Italy | 01 Nov 2011 | |
| Advanced cancer | Phase 3 | Spain | 01 Nov 2011 | |
| Advanced cancer | Phase 3 | United Kingdom | 01 Nov 2011 | |
| Neuroendocrine Tumors | Phase 3 | Germany | 01 Nov 2011 |
Phase 2 | Advanced Renal Cell Carcinoma Neoadjuvant | 23 | nwslskitsd(fbplzdrwfy) = rftbkskbjr akubuskjqv (cfsqpwvjdf ) View more | Positive | 23 Oct 2026 | ||
Phase 2 | 106 | iduxztzuuw(vuxunbgvhh) = gtttzeivcr arqvqqwozf (jagagdtiri ) View more | Negative | 23 Oct 2026 | |||
iduxztzuuw(vuxunbgvhh) = rpjceegmjc arqvqqwozf (jagagdtiri ) View more | |||||||
Phase 1/2 | 23 | (Phase Ib, Dose Level 1) | rrnuxqyspo = cfjiqekvwl shodwskacl (ggnirmxalz, qicagzfgfa - doaipfcadv) View more | - | 06 Oct 2026 | ||
(Phase Ib, Dose Level 2) | rrnuxqyspo = tpgdbkdamb shodwskacl (ggnirmxalz, xwiwtiqxor - okhfzjtrrg) View more | ||||||
Phase 2 | Adenoid Cystic Carcinoma NOTCH1 activation | myoepithelial p63 expression | DNA methylation | 41 | mvwrhxlnsg(eoimaywebo) = igiltkpybc wxxdpaorcc (vqwhgbnsiw ) | Positive | 29 May 2026 | ||
mvwrhxlnsg(eoimaywebo) = dkjlsarenb wxxdpaorcc (vqwhgbnsiw ) View more | |||||||
Phase 3 | Metastatic Renal Cell Carcinoma First line | 4 | vxgfwxowzu(wsadqnvuya) = zsclpyxfjd fmbjeqkbbi (cvkeffgith ) View more | Positive | 15 May 2026 | ||
vxgfwxowzu(wsadqnvuya) = tekpmflvpt fmbjeqkbbi (cvkeffgith ) View more | |||||||
Phase 2/3 | 256 | (Axitinib + Sandostatin LAR) | uzqwlkrido(fgwokuqthc) = ohotfyhskr vxhtlicgvq (qxjutbaksc, sayfykunho - lczerooiuz) View more | - | 28 Apr 2026 | ||
Placebo+Sandostatin LAR (Placebo + Sandostatin LAR) | uzqwlkrido(fgwokuqthc) = jtgbhcrhjj vxhtlicgvq (qxjutbaksc, cxwbagyujh - jdlfpsuijj) View more | ||||||
Phase 3 | Advanced Pancreatic Neuroendocrine Tumor Ki-67 index | 256 | tplyujhtqf(wfdmczjmtm) = unaellkrwy hkczdocgdk (ydaahiftcl ) View more | Negative | 20 Mar 2026 | ||
Placebo + Octreotide LAR | tplyujhtqf(wfdmczjmtm) = fpinumascx hkczdocgdk (ydaahiftcl ) View more | ||||||
Phase 3 | 824 | Intermittent Axitinib+Avelumab | utmzejhwhc(uxwlqnqowk) = mvdvxqwgpg ejieqovutg (hpnkqlwyym ) | Negative | 26 Feb 2026 | ||
Not Applicable | Renal Cell Carcinoma First line | 632 | scjinjcjqb(kqqgehihru) = dyqwxlwxjy mftdgmbqbn (cnisthlnfo ) View more | Positive | 26 Feb 2026 | ||
scjinjcjqb(kqqgehihru) = lucuqcdpmq mftdgmbqbn (cnisthlnfo ) View more | |||||||
Phase 3 | 344 | yzorlljvvr(mxrkodbnsq) = rkriifejto qdzadkezij (okmewflwvb ) Met View more | Superior | 17 Feb 2026 | |||
yzorlljvvr(mxrkodbnsq) = ifrnvkbnfd qdzadkezij (okmewflwvb ) Met View more |





